
India’s Cervavac HPV Vaccine Secures WHO Prequalification for Global Distribution
The story in brief
India’s Cervavac HPV vaccine, developed by Serum Institute of India, received WHO prequalification on October 5, 2026. The vaccine targets HPV strains 6, 11, 16, and 18 and is approved for use in individuals aged 9 through 26. It was developed with collaboration from DBT, BIRAC, WHO-IARC, and the Gates Foundation. The prequalification allows UN agencies to procure the vaccine for global distribution, enhancing access to HPV-related disease prevention.